These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 21595177

  • 21. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
    Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R171. PubMed ID: 24286269
    [Abstract] [Full Text] [Related]

  • 22. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT.
    Drugs; 2009 Oct 22; 69(15):2035-43. PubMed ID: 19791825
    [Abstract] [Full Text] [Related]

  • 23. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
    Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.
    Ann Rheum Dis; 2014 May 22; 73(5):909-12. PubMed ID: 24385201
    [Abstract] [Full Text] [Related]

  • 24. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F, Niccoli L, Goletti D.
    J Rheumatol Suppl; 2014 May 22; 91():56-64. PubMed ID: 24789001
    [Abstract] [Full Text] [Related]

  • 25. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.
    Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ.
    Semin Arthritis Rheum; 2013 Aug 22; 43(1):9-17. PubMed ID: 23290690
    [Abstract] [Full Text] [Related]

  • 26. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E.
    Ann Rheum Dis; 2011 Feb 22; 70(2):266-71. PubMed ID: 21097801
    [Abstract] [Full Text] [Related]

  • 27. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.
    Daïen CI, Morel J.
    Mediators Inflamm; 2014 Feb 22; 2014():386148. PubMed ID: 24523570
    [Abstract] [Full Text] [Related]

  • 28. Targeted therapy in rheumatoid arthritis.
    Köller MD.
    Wien Med Wochenschr; 2006 Jan 22; 156(1-2):53-60. PubMed ID: 16465614
    [Abstract] [Full Text] [Related]

  • 29. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 22; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL.
    J Rheumatol; 2011 Nov 22; 38(11):2355-61. PubMed ID: 21885487
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML, all departments of rheumatology in Denmark.
    Ann Rheum Dis; 2011 Jul 22; 70(7):1216-22. PubMed ID: 21551512
    [Abstract] [Full Text] [Related]

  • 32. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL.
    Arthritis Res Ther; 2015 Nov 11; 17():319. PubMed ID: 26555431
    [Abstract] [Full Text] [Related]

  • 33. The use of biological agents in the treatment of rheumatoid arthritis.
    Fan PT, Leong KH.
    Ann Acad Med Singap; 2007 Feb 11; 36(2):128-34. PubMed ID: 17364080
    [Abstract] [Full Text] [Related]

  • 34. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct 11; 18(103):198-201. PubMed ID: 19882783
    [Abstract] [Full Text] [Related]

  • 35. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A, Wallman JK, Kristensen LE.
    Arthritis Res Ther; 2016 Feb 19; 18():51. PubMed ID: 26892115
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019 Feb 19; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 37. My treatment approach to rheumatoid arthritis.
    Davis JM, Matteson EL, American College of Rheumatology, European League Against Rheumatism.
    Mayo Clin Proc; 2012 Jul 19; 87(7):659-73. PubMed ID: 22766086
    [Abstract] [Full Text] [Related]

  • 38. [Management for TNF failure].
    Mukai M.
    Nihon Rinsho; 2007 Jul 19; 65(7):1299-307. PubMed ID: 17642247
    [Abstract] [Full Text] [Related]

  • 39. [New therapies for rheumatoid arthritis].
    Salgado E, Maneiro JR.
    Med Clin (Barc); 2014 Nov 18; 143(10):461-6. PubMed ID: 24461738
    [Abstract] [Full Text] [Related]

  • 40. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
    Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K.
    Semin Arthritis Rheum; 2013 Aug 18; 43(1):39-47. PubMed ID: 23453683
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.